29 dec: Aktier/middag: Vestas tager bundplacering trods nye ordrer
29 dec: Skidt år for vindmølleaktier - trods god ordreaktivitet
29-12-2016 13:00:12

Bavarian Nordic Initiates Trial of CV301 in Combination with Nivolumab in Patients with Lung Cancer

Relateret indhold
23 apr - 
Bavarian-aktien har oplevet markant shortangreb efter r..
20 apr - 
Fredagens aktier: Mærsk i fuld fart frem - Vestas og Ba..
20 apr - 
Bavarian: Udenlandske kapitalfonde øger væddemålet på k..
Relateret debat
00:52 - 
model update på bava, da bava ikke holdte 175 med stram..
24 apr - 
Det er virkelig psyko hvordan shorterne i øjeblikket st..
24 apr - 
MEsell den er faldet rigtig meget men den kan nok komme..

  • Study is exploring potential benefits of combining a cancer vaccine and PD-1 checkpoint inhibitor

COPENHAGEN, Denmark, December 29, 2016 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced the initiation of a clinical trial combining its proprietary cancer immunotherapy candidate, CV301, with the anti-PD-1 drug, OPDIVO® (nivolumab) from Bristol-Myers Squibb. The study is enrolling patients with non-small cell lung cancer (NSCLC) who have failed prior therapy.

 

The trial will begin with a Phase 1 safety component, enrolling up to 40 patients; the Phase 2 portion of the study will enroll 120 patients who will be randomized to receive either nivolumab (monotherapy) or a combination of CV301 and nivolumab. The study will enroll patients from up to 20 clinical sites throughout the United States. Detailed information on the trial can be found at http://clinicaltrials.gov/ct2/show/NCT02840994.

The rationale for this combination approach is for the vaccine to generate a tumor specific T cell response and allow the checkpoint inhibitor to maintain that immune effect by preventing the tumor from turning that response off.

While the primary endpoint of the study is overall survival, numerous secondary endpoints including response rate, progression free survival and duration of response will be evaluated and offer the potential for an early efficacy signal, prior to an overall survival endpoint.

"We are pleased to announce the initiation of this study, which marks the entry for Bavarian Nordic into lung cancer. While CV301 has shown the ability to generate immune responses to tumor-associated antigens in a variety of cancers, this study is the first seeking proof-of-concept for a promising combination approach and we look forward to the results as well as to advance CV301 as combination therapy in additional indications over the next years," said Paul Chaplin, President & CEO of Bavarian Nordic.

About CV301

CV301 is an immunotherapy candidate which is being developed under a CRADA with the National Cancer Institute (NCI).

CV301 targets two tumor-associated antigens, CEA and MUC-1, which are over-expressed in multiple solid tumors, including lung, bladder and colorectal cancer. Similar to PROSTVAC®, CV301 uses a prime/boost dosing schedule. CV301 incorporates a modified version of vaccinia (MVA-BN, a proprietary technology of Bavarian Nordic) as a priming dose, followed by multiple fowlpox boosts, and encodes the TRICOM costimulatory molecules.

A precursor version of CV301 has been tested in six NCI-sponsored clinical trials in various cancers, and a Phase 2 study in bladder cancer is currently ongoing. More than 300 patients have been treated with the product candidate.

About OPDIVO (nivolumab)

Marketed by Bristol-Myers Squibb, OPDIVO is an immune checkpoint inhibitor (anti-PD-1 therapy) approved for treatment of patients with advanced NSCLC in the second line setting, among other indications. OPDIVO has demonstrated superior overall survival across histologies, versus chemotherapy, in two pivotal Phase 3 trials in patients with advanced NSCLC.

About Bavarian Nordic

Bavarian Nordic is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases, based on the Company's live virus vaccine platform. Through long-standing collaborations, including a collaboration with the U.S. government, Bavarian Nordic has developed a portfolio of vaccines for infectious diseases, including the non-replicating smallpox vaccine, IMVAMUNE®, which is stockpiled for emergency use by the United States and other governments. The vaccine is approved in the European Union (under the trade name IMVANEX®) and in Canada. Bavarian Nordic and its partner Janssen are developing an Ebola vaccine regimen, which has been fast-tracked, with the backing of worldwide health authorities, and a vaccine for the prevention and treatment of HPV. Additionally, in collaboration with the National Cancer Institute, Bavarian Nordic has developed a portfolio of active cancer immunotherapies, including PROSTVAC®, which is currently in Phase 3 clinical development for the treatment of advanced prostate cancer. The company has partnered with Bristol-Myers Squibb for the potential commercialization of PROSTVAC. For more information visit www.bavarian-nordic.com or follow us on Twitter @bavariannordic.

Forward-looking statements

This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

Contacts

Rolf Sass Sørensen

Vice President Investor Relations (EU)

Tel: +45 61 77 47 43

Seth Lewis

Vice President Investor Relations (US)

Tel: +1 978 341 5271

2016-12-29-en


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Bavarian Nordic A/S via Globenewswire

Vedhæftet fil: 2016-12-29-en.pdf

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
19 apr
BAVA
      Vedr. shortsqeeze mm. og den ekstreme kursmanipulation der dagligt foregår på Nasdaq Kbhvn. T..
19
18 apr
BAVA
Jeg tror nok der er nogen, der sidder lidt længere ude på stolen i dag. Det skulle ikke undre mig om..
11
21 apr
BAVA
Er en velkendt måde for spekulanter og pensionskasser at tjene penge på. Hvis frosten kommer tjener ..
8
20 apr
BAVA
Det er ikke hans skyld. Det er disse shortere der bare skal have dens mindste anledning til at sælge..
5
18 apr
BAVA
@Henry1, jeg må indrømme, at det af og til er bare en anelse trættende at læse dine Bavarian indlæg...
5
24 apr
BAVA
Ejer den selv men i morgen skal vi nok under 160. USA bløder.
4
24 apr
BAVA
Summary Posted: 04/2018 Combination immunotherapy clinical trial for prostate cancer patients with r..
4
18 apr
BAVA
GSA Capital Partners LLP holds a short position at 0.54 % in shares issued by Bavarian Nordic A/S Gi..
4
20 apr
BAVA
Jeg synes jeg kan se et mønster.Genmab, Bavarian, Pandora.   Man udnytter en usikkerhed i markedet. ..
3
20 apr
BAVA
Arrowstreet Capital Limited Partnership holds a short position at 1.38 % in shares issued by Bavaria..
3

DFDS får ny færge til Den Engelske Kanal

24-04-2018 10:41:49
Rederiet DFDS har indgået en tiårig bareboat charteraftale med Stena RoRo om en nybygget færge af typen ro-pax til levering i begyndelsen af 2021.Det skriver selskabet i en pressemeddelelse. Færgen skal sejle på Den Engelske Kanal, hvor den bliver en af seks færger, der sejler på to ruter. Den nye færge skal erstatte den ældste af slagsen, der blev taget i bygget i 1991. Den nye færge får højere f..

Aktier/tendens: DSV og Genmab løber med opmærksomheden

24-04-2018 08:26:35
Der er lagt op til en stille åbning på det danske aktiemarked tirsdag morgen, hvor investorerne vil have fokus på DSV efter regnskabet fra en af selskabets nærmeste rivaler, mens Genmab har fået løftet kursmålet hos JPMorgan.Det amerikanske aktiemarked faldt en spids efter dansk børslukketid mandag, men tirsdag morgen peger de asiatiske aktier op. Samtidig stiger futures marginalt for det tyske DA..

Tivoli/CEO: Ny sæson og Tivoli Hjørnet øger omsætningen

23-04-2018 13:39:42
Den nye sæson hos forlystelsesparken Tivoli, Vinter I Tivoli, har sammen med åbningen af Tivoli Hjørnet bidraget til, at omsætningen er steget i første kvartal 2018.Det vurderer Lars Liebst, der er administrerende direktør i Tivoli. - Vi har haft åbent til Vinter i Tivoli og åbnet vores hjørne, og det har været gode ting. Det kan man se på omsætningen, siger Lars Liebst til Ritzau Finans.Nettoomsæ..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Aktier/tendens: DSV og Genmab løber med opmærksomheden
2
Vestas-konkurrent vinder ordre på 225 megawatt i USA
3
Tirsdagens aktier: Grønt Novo-træk kunne ikke sikre samlet C25-plus
4
GE har fundet rugekassen til sin nye gigantmølle på 12 MW
5
Novo/Sydbank: Stærk vækst hos Lilly lover godt

Relaterede aktiekurser

Bavarian Nordic A/S 164,50 -1,1% Fald i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2018  Disclaimer Cookie- og privatlivspolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
25. april 2018 02:41:00
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20180423.5 - EUROWEB2 - 2018-04-25 02:41:00 - 2018-04-25 02:41:00 - 1 - Website: OKAY